Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company’s PDAOAI technology with advanced robotics provided through its collaboration with TechForce Robotics, targeting pharmaceutical, biotechnology and advanced therapeutics companies seeking to modernize manufacturing operations.

The platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. Oncotelic also plans to showcase progress with its Deciparticle nanomedicine platform, including SAPU003, its clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The announcement underscores Oncotelic’s push into AI-driven contract manufacturing services, leveraging its proprietary technology to address industry needs for automation and compliance.

Oncotelic’s PDAOAI platform, originally developed for drug discovery and lab automation, now underpins the GMP manufacturing services. The company’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, further supports the platform’s development. Through the partnership with TechForce Robotics, Oncotelic aims to integrate purpose-built robotics into pharmaceutical manufacturing workflows. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys automation solutions for service, hospitality, and pharmaceutical applications.

The launch at BIO 2026 highlights the growing intersection of artificial intelligence and pharmaceutical manufacturing. By offering AI-assisted GMP services, Oncotelic positions itself to help biotech and pharma companies reduce manual errors, improve batch record accuracy, and accelerate production timelines. The platform’s digital quality systems and process monitoring capabilities could address regulatory compliance challenges faced by manufacturers adopting Industry 4.0 technologies.

Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, focuses on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also owns 45% of GMP Bio, a joint venture advancing complementary drug candidates. For more information, visit www.oncotelic.com and www.techforcerobotics.com.

This development matters as it signals a shift toward AI-enabled contract manufacturing in the pharmaceutical industry, potentially lowering barriers for smaller biotech firms to access advanced GMP capabilities. The integration of robotics and AI could also enhance production consistency and data integrity, key factors in FDA inspections and drug approvals. As the industry faces pressure to reduce costs and accelerate time-to-market, Oncotelic’s platform may offer a competitive edge for companies looking to digitize their manufacturing processes.